Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a probiotic pill improve vaginal health?

NCT ID NCT06830122

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether taking a probiotic called Lactobacillus crispatus LCr86 by mouth could improve vaginal health in women with an intermediate vaginal microbiome. 80 women participated, taking either the probiotic or a placebo for 8 weeks. Researchers measured changes in vaginal bacteria scores, pH, and inflammation markers to see if the probiotic helped restore a healthy balance.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Lactobacillus crispatus LCr86 probiotic
What this could lead to
If successful, this could point toward a simple probiotic supplement to help restore healthy vaginal bacteria and reduce the risk of bacterial vaginosis.
What could go wrong
This is a small, completed trial with 80 participants. Results may not apply to all women, and the probiotic may not work for everyone. Long-term benefits are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Started

Jul 2025

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 50 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Women of childbearing age over 19 years of age and under 50 years of age. 2. A person with a score of 4-6 on the Nugent core. 3. A person who agrees to participate in the human application test before the human application test begins and has prepared the written consent form. 4. A person who agrees to follow the contraception methods permitted by PI. Exclusion Criteria: 1. Those who are currently being treated for severe cardiovascular system, immune system, respiratory system, gastrointestinal tract/liver and biliary system, kidney and urinary system, nervous system, musculoskeletal system, psychiatric, infectious disease, tumor and malignant. 2. The subjects who treated for vaginal or urinary tract infection as of within 3 months (e.g., candidiasis, trichomonas infection, gonorrhea, chlamydial infection, etc.). 3. The subjects with vaginal or urinary tract bleeding, or abnormality. 4. The subjects who has been given antibiotics, antimicrobial agents, steroids, immunosuppressants, estrogen-based drugs (pneumonia-related drugs are allowed) within 4 weeks of visit 1 (but those who used them within 2 weeks of visit 1 cannot participate in the test). 5. The subjects who has consumed health functional foods related to improving immune function and vaginal health. 6. The subjects who has administered probiotics and prebiotics within two weeks based on visit 1 or has continuously administered or ingested fermented milk and lactobacillus products. 7. Allergic constitution or hypersensitivity to known components of the study drug. 8. The subjects who has received salivary treatment for sedimentation, women's cleansers, vaginal sanitizers, left fumigation, and vaginal health within two week of screening visit. 9. The subjects with unregulated hypertension (above 160mmHg or 90mmHg of blood pressure). 10. The subjects who AST (GOT) or ALT (GPT) is at least three times the normal limit of the testing agency. 11. The subjects who are sensitive or allergic to the ingredients of this human-applied test food. 12. Subjects who are pregnant, breastfeeding, or planning to conceive within three months. 13. If the daily alcohol intake is more than 20g. 14. Excessive smokers (≥20 pieces/day). 15. The subjects who has participated in another interventional clinical trial within three month of the commencement of this trial or who has a plan to participate in another interventional clinical trial (including a human application test) after the commencement of this human application test. 16. The subjects who is deemed inappropriate by the human application test testers for this human application test. 17. Other vaginitis: Trichomonas vaginalis (TV) infection or fungal infection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Patients with bacterial vaginosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Zhao ruihang

    Suzhou, Jiangsu, 215200, China